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ABSTRACT
The medical device industry is highly profitable and projected to experience double digit growth
well into the future. The five top performing American medical device companies offshore some
core and non-core value chain activities to realize lower production costs, higher innovation, and
faster time to market. This case examines the offshoring decision of Acesco Medical Devices - a
medium-size company that produces neurology, orthopedics, and cardiovascular products. It
considers the tradeoffs between corporate social responsibility, as it pertains to workforce
reductions in the United Sates, and the substantial strategic benefits of offshoring to India.
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INTRODUCTION

J

im Fraser pondered the proposal to relocate some of Acesco Medical Devices, Inc’s activities to India.
There are compelling cost savings and attractive new market opportunities from offshoring, but the
prolonged U.S. recession and dour domestic political mood are reasons for caution. In particular, exporting
high paying R&D and manufacturing jobs could be construed as yet another example of corporate greed.
Nevertheless, recent developments in the industry’s competitive and external environments offer powerful reasons
to do so. Any decision must balance corporate social responsibility as it pertains to job loss in the U.S. against
considerable benefits from offshoring.
Exhibit 1: Financial Data for Selected Medical Device Firms Engaging in Offshoring (2008-2012)
2008
2009
2010
2011
2012
––––––––––––––––––––––––––– $ millions ––––––––––––––––––––––––––––––
Sales
Johnson & Johnson
63,747
61,897
61,587
65,030
67,224
General Electric
112,769
103,777
100,437
94,523
100,149
Siemens
77,327
76,651
75,978
73,275
78,296
Medtronic, Inc.
13,515
14,599
15,817
15,933
16,184
Baxter International
12,348
12,562
12,843
13,893
14,190
Net Profit
Johnson & Johnson
12,949
12,266
13,334
9,672
10,514
General Electric
17,410
11,025
11,644
14,151
13,641
Siemens
5,886
2,497
4,068
6,321
4,590
Medtronic, Inc.
2,231
2,169
3,099
3,096
3,617
Baxter International
2,014
2,205
1,420
2,224
2,326
Net Worth
Johnson & Johnson
42,511
50,588
56,579
57,080
64,826
General Electric
104,665
117,291
118,936
116,438
123,026
Siemens
27,380
27,287
29,096
32,156
31,302
Medtronic, Inc.
11,536
12,851
14,629
15,968
17,113
Baxter International
6,229
7,191
6,567
6,585
6,938
–––––––––––––––––––––––––––––––– % –––––––––––––––––––––––––––––––
Pretax Profit/Sales
Johnson & Johnson
26.6
25.5
27.5
19.0
20.5
General Electric
17.0
10.0
14.1
21.3
17.4
Siemens
3.7
5.1
7.6
13.1
9.3
Medtronic, Inc.
21.3
17.8
25.1
23.4
25.6
Baxter International
19.8
21.8
14.7
20.2
20.4
Source: Company Annual Financial Statements
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The global medical device industry is lucrative with 2012 revenues of $350 billion that are expected to
grow to $440 billion by 2018. The U.S. is the largest medical device market with 2012 sales of $120.4 billion
projected to grow to $156.8 billion in 2018. The top thirty-two American companies each enjoy more than $1 billion
in annual revenue and account for approximately 40% of the world market (Frost and Sullivan, 2012). American
firms also face favorable domestic developments, such as a burgeoning number of Baby Boomers who consume
significant amounts of healthcare, especially in the later stages of life; strong sales despite the prolonged recession;
and increased demand driven by the large number of newly insured under Obamacare. The industry is lucrative and
firms, engaged in offshoring experienced strong performance (Exhibit 1).
COMPANY BACKGROUND
Acesco Medical Devices, Inc. is an original equipment manufacturer focused on the neurology,
orthopedics, and cardiovascular segments. All three exhibited double digit growth rates that are expected to continue
into 2018 (Transparency Market Research, 2012). The company, lagging industry trends, manufactures exclusively
within the United States. By using Food and Drug Administration (FDA) approved domestic contractors to create
components and subassemblies. Acesco reduces costs and time-to-market. This frees it to focus on developing new
and innovative products - an increasingly important competitive dimension. Additionally, domestic contractors tend
to be more reliable and trustworthy than foreign counterparts. Some firms contracting with Chinese manufacturers
experienced catastrophic quality control issues and technology leakage (Sun, 2012). Despite those advantages, as
product designs become standardized and foreign markets become more attractive, offshoring becomes a
competitive necessity. Foreign subcontractors not only offer cost and time savings but also bring deep knowledge of
the regulatory environment in their home markets and the markets they sell to.
Although Acesco’s performance is strong, recent developments pose uncertainties for the U.S. market. The
Patient Protection and Affordable Care Act of 2010 will impose a 2.3% excise tax, effective in 2013, on total
company revenues, regardless of profitability. In other words, a firm may incur losses and still be liable for the
excise tax. Proposed reforms to the FDA-approval process, expected to hamper innovation and raise costs, will
cause firms to locate some activities in countries with lower labor costs and favorable regulation. Furthermore,
increasingly stringent Medicare reimbursement requirements, smaller reimbursements, and other cost-cutting
pressures will make emerging markets, such as Brazil and China, attractive (Bain and Company, Inc., 2012).
MEDICAL DEVICE INDUSTRY SWOT ANALYSIS
Strengths
Research Infrastructure and Venture Funding
Medical research and teaching institutions in the U.S. rank among the best in the world. There are 141
accredited medical schools, approximately 350 major teaching hospitals, and 51 Veterans Affairs medical centers
(Association of American Medical Colleges, 2013). Close collaboration between research labs, hospitals and venture
capitalists has helped rapidly commercialize innovations. Indeed, recent landmark technologies, such as implantable
cardiac defibrillators, arose from such collaboration (National Venture Capital Association, 2013).
Market Size and Strength of American Companies
The U.S. is the largest market for medical devices with sales of $120.4 billion in 2012. The top thirty-two
American companies each enjoy more than $1 billion in annual revenue. Additionally, American companies
dominate the $350 billion global medical device industry with approximately 40% of the market (Frost and Sullivan,
2012).
Consumer Trends
The ubiquity of mobile devices, such as smartphones and tablets, is driving the consumerization of medical
devices. With medical associations and health care providers posting information on the Web, patients are now
376
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making treatment decisions in conjunction with healthcare providers. This trend creates opportunities for medical
companies that can produce new devices and the necessary software to streamline transfer of diagnostic results to
Internet and mobile reporting platforms (West, 2012).
Weaknesses
Regulation
A recent study comparing the FDA and European Medicines Agency (EMA) device approval processes
reported that the FDA’s complex regulation and excessive bureaucracy hindered innovation and decreased American
firms’ competitiveness in the global marketplace. The study noted that the FDA review process is almost twice as
long as that of the EMA with a six-month mean review time in the U.S. compared to three months in Europe. Short
review times are important because regulatory requirements play a significant role in manufacturers’ decisions to
develop new products. Firms in countries with simpler and more efficient regulatory approval processes are quicker
to market and reap first mover advantages (Boston Consulting Group, 2012).
Shrinking STEM Pool
The U.S. faces a substantial dearth of individuals with science, technology, engineering, and math skills
(STEM). This shortfall is partly offset by the 85,000 H1B visas offered to foreign nationals with STEM backgrounds
(Microsoft, Inc., 2013). The I-Squared or Immigration Innovation Act proposes to raise the cap to 115,000 visas
with annual increases to a maximum of 300,000. The bill is currently generating substantial controversy because of
persistent U.S. underemployment.
No Permanent R&D Tax Credit
The R&D Tax Credit offers companies an incentive to invest in high risk research that may result in viable
products many years in the future. In its current form, the R&D tax credit has been temporarily extended since 1981.
Historically it has generated $2 of economic growth for every $1 granted, created high paying jobs, increased
productivity, and established the foundation for American competitiveness in a variety of global industries. Prior to
1991, the United States was preeminent among OECD nations in the effectiveness of the R&D tax credit but by
2008 had fallen to 17th. Many countries worldwide use permanent tax incentives to encourage domestic R&D. This
tax credit creates an advantage for foreign firms (Deloitte, Touche, Tohmatsu Limited, 2013).
Opportunities
Burgeoning and Aging Populations
The U.S. population is mature with a median age of 36.9 years and 13.1% of the population 65 and over
(U.S. Census Bureau, 2012). Other developed, high-income economies are also aging. Japan, for example, has a
median age of 45 with 22.9% of the population age 65 and over (Japan Statistical Yearbook, 2012). The global
population is projected to rise to 9 billion by 2050. Of this number, 15% or 1.35 billion people will be age sixty and
over (United Nations Department of Economic and Social Affairs Population Division, 2004). This bodes well for
the industry because the elderly consume a disproportionate amount of health care resources.
Emerging Economies
Emerging markets will become more important as U.S. regulations and increasingly stringent Medicare
reimbursements erode margins. As emerging economies prosper and their populations age, demand will increase
(Transparency Market Research, 2012). In addition, less stringent regulations in Brazil and India will likely cause
the medical device industry to follow the model of consumer product firms which use emerging markets as a
laboratory to develop low cost products that are subsequently sold in a large number of other markets.
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Threats
Medical Reimbursements
Reimbursements, which comprise a large percentage of revenue for medical device manufacturers, are
expected to become more difficult to obtain. As employers, governments, and private party payers shift a larger
percentage of healthcare costs to individuals and providers, device manufacturers will likely experience a decline in
revenue (White & Ginsburg, 2012). In contrast, emerging economies, such as Brazil, India, and China, are expected
to offer easier reimbursement terms.
Shifts in Venture Industry Focus
Many medical technology innovations are incubated in startups that are later acquired by established
companies with resources to implement large-scale rollouts. Emerging markets are increasingly attractive to
American venture capital because of higher economic growth rates, a strong desire for external investment, and
favorable regulation. The U.S. market is less attractive because of complex and cumbersome regulations, difficulty
in obtaining reimbursements, and an administration that favors greater regulation. Emerging markets, such as China
and India, offer stronger growth, a comparatively streamlined medical device approval process requiring less time
and money and large talent pools with vital STEM skills. It is likely that growing venture investments outside the
U.S. will give rise to many startup device manufacturers that will be acquired by large medical device companies
seeking to fill their product pipelines (National Venture Capital Association, 2013).
OFFSHORING IN INDIA
India offers a large pool of technical talent with over 300,000 engineers and 150,000 software developers
graduating every year. Those engineers, paid an average of 18.3% of an American counterpart, represent a
substantial cost advantage to firms engaged in offshoring (Pore, et al, 2008). India’s highly educated, English
speaking labor force is also able to develop software solutions, create new hardware designs, and engage in research
and development. They are also likely to create integrated software platforms that facilitate transfer of diagnostic
results from medical devices to Internet or mobile platforms used by patients. Industry experts believe that
delegating product development, design, and manufacturing to contractors or foreign subsidiaries will reduce costs,
truncate the product development cycle, and shorten time-to-market.
Offshoring Political Considerations
Although the savings and competitive advantages from offshoring are considerable, Fraser understood that
the sluggish post-2008 economy put the nation in a dour mood. Public debate over corporate America’s greed,
hollowing out of the nation’s industrial base, and strong corporate performance despite anemic job growth, are
reasons for concern. Offshoring, coincidentally, would require Acesco to temporarily locate some foreign
researchers and engineers to the U.S. where they would be trained by workers they are replacing. The company
would likely face negative publicity that could tarnish its reputation and potentially invite a backlash.

2006
2007
2008
2009
2010
2011
2012
Source:

Exhibit 2: U.S. Employment in Selected Manufacturing Industries (2006-2012)
U.S. Labor Force
Computer and Electronic Products
Electrical Equipment and Appliances
(000s)
%
(000s)
%
(000s)
%
144,417
100.0
1,307.5
100.0
432.7
100.0
146,050
101.1
1,272.5
97.3
429.4
99.2
145,373
100.6
1,244.2
95.1
424.3
98.0
139,894
96.8
1,136.9
86.9
373.6
86.3
139,077
96.3
1,094.6
83.7
359.5
83.1
139,882
96.8
1,103.5
84.3
366.1
84.6
142,469
98.6
1,093.7
83.6
370.1
85.5
Bureau of Labor Statistics, data not seasonally adjusted

American job losses have fallen disproportionately on manufacturing and despite improved employment in
2012, manufacturing still lagged behind the overall economy. Exhibit 2 compares changes in employment between
378

Copyright by author(s) Creative Commons License CC-BY

2013 The Clute Institute

Journal of Business Case Studies – September/October 2013

Volume 9, Number 5

2006 and 2012. Overall U.S. employment is compared to that of two high margin manufacturing industriescomputers and electronics (C&E) and electrical equipment and appliances (E&A). An examination of the post-2008
crash shows overall U.S. employment in 2009 fell 3.2% relative to the 2006 baseline. During the same period,
employment in C&E declined 13.1% while E&A fell 13.7%. By 2012, overall U.S. employment was just 1.4% lower
than 2006 while C&E declined 16.4% and E&A fell 14.5%.
Although conventional wisdom asserts that job losses in manufacturing would be offset by new jobs
created in the service sector, it presents an incomplete picture of the impact on workers. Exhibit 3 depicts earning
patterns of American workers who lost jobs between January 2009 and December 2011 and subsequently found
employment in 2012. Of the 3,003,000 unemployed workers, 630,000 (20.9%) found jobs that paid 20% or less than
their previous wage; 538,000 (17.9%) found jobs with wages equal or above, but within 20% of their previous
salary, and 352,000 (11.7%) were hired at 20% or more than their previous income. The picture for durable goods
manufacturing - the category that encompasses medical devices - is less favorable. Of 457,000 workers who lost
jobs, 125,000 (27.3%) found jobs that paid 20% or less than their former wage; 53,000 (11.5%) found jobs equal or
above, but within 20% of their pre-unemployment wage; and 48,000 (10.5%) were hired at 20% or more than their
prior wage. The numbers suggest that workers in durable goods manufacturing did not fare as well as the average for
all employment categories.
With U.S. manufacturing employment lagging behind the overall economy, high profits, buoyant device
company stock prices, and substantial strategic advantages from offshoring, Fraser’s decision must tread a careful
path between future opportunities and corporate social responsibility.
Exhibit 3: Displaced U.S. Workers (1) Who Lost Full-Time, Tenured* Wage and Salary Jobs between
January 2009 & December 2011 and were Re-employed in January 2012 by Industry
of Lost Job and (2) Earnings Level of New Job (1,000’s)
Industry Of Worker Of Lost
20%Or More
Below, But
Equal Or Above, 20% Or More
Total
Job
Below
Within 20%
But Within 20%
Above
Total Who Lost Full-Time
3,003
630
408
538
352
Wage & Salary Jobs
Mining, Quarrying, and Oil and
15
12
------Gas Extraction
Construction
393
89
49
64
43
Manufacturing
645
171
108
87
64
Durable Goods
457
125
74
53
48
Nondurable Goods
188
46
34
34
16
Transportation and Utilities
139
22
26
15
20
Wholesale and Retail Trade
368
84
42
77
52
Information
95
27
14
8
10
Financial Activities
255
52
29
46
27
Professional and Business
373
56
60
93
36
Services
Education and Health Services
257
29
30
67
21
Leisure and Hospitality
174
25
17
31
22
Other Services
91
20
10
18
11
Government Wage and Salary
138
30
13
22
33
Workers
Source: Bureau of Labor Statistics, data not seasonally adjusted. *Tenured refers to 3 or more years on job lost because of plant
or company closing, insufficient work, or abolition of position or shift.
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